tanibirumab

A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Background VEGF is a highly selective mitogen that serves as the central regulator of tumor angiogenesis by mediating endothelial… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2017
2017
e13522Background: Treatment of recurrent GBM remains a challenge. The VEGF signal transduction pathway is upregulated in GBM. We… Expand
Is this relevant?
Review
2016
Review
2016
INTRODUCTION Anti-angiogenetic agents are currently the standard of care in metastatic CRC patients. Bevacizumab, aflibercept… Expand
  • table 1
Is this relevant?
2015
2015
SummaryBackground Tanibirumab is a fully human monoclonal antibody to vascular endothelial growth factor receptor 2 (VEGFR-2). We… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2013
2013
PURPOSE The study investigated the effect of intravitreally administered tanibirumab, a fully human monoclonal antibody against… Expand
Is this relevant?
Review
2011
Review
2011
Vascular endothelial growth factor (VEGF) binds to its receptor (VEGFR) and stimulates angiogenesis, an important step in tumor… Expand
  • figure 1
  • figure 2
Is this relevant?